Alpelisib 300 mg

DRUG2 trials

Conditions

Healthy Adult ParticipantsInsulin ResistanceNon-Alcoholic Fatty Liver DiseaseObesity & OverweightOverweight and ObesityPrediabetic StateType 2 Diabetes

Phase 1

Human Models of Selective Insulin Resistance: Alpelisib, Part I

RecruitingNCT06354088

Columbia UniversityInsulin Resistance, Prediabetic State, Overweight and Obesity +1

Start: 2024-04-24End: 2026-12-31Target: 32Updated: 2026-08-24

Alpelisib Challenge Test (ACT)

RecruitingNCT07778524

Columbia UniversityInsulin Resistance, Type 2 Diabetes, Obesity & Overweight +1

Start: 2026-09-02End: 2028-08-31Target: 15Updated: 2026-09-03

Alpelisib 300 mg

Sponsors

Conditions

Phase 1